Provided by:



Duhring Dermatology Lectureship Conference 2023-2024

Duhring Dermatology Lectureship Conference 2023-2024 - The skin we live in: the human skin microbiome - 6/1/2023

June 1, 2023

11:00 AM - 12:00 PM

Target Audience

This program has been designed for Dermatology, Dermatology - Dermatology, Dermatology - Pediatric Dermatology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe how to Increase rate or frequency of proper accurate diagnosis by physicians and nurses of patients with a rare or difficult skin condition
- 2 Discuss the therapeutic management of rare dermatologic diseases
- 3 Discuss how to improve recognition by physicians and nurses to treat dermatosis in the dermatologic patient

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Discuss features of the skin microbiome in healthy individuals
- 1 Review potential applications of skin microbiome research
- 2 Describe skin microbiome differences in certain immunodeficient patient populations

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Acknowledgement of Commercial Support*

For more information, please contact Dawn MacMillan, Sarah Scheuring (215) 898-4758, (215) 573-3387

dawn.macmillan@uphs.upenn.edu, sscheu@upenn.edu

None



Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producting, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Thomas Leung, MD, PhD	Course Director	Nothing to disclose - 11/16/2022
Heidi Kong, MD, MS	Faculty	Nothing to disclose - 12/30/2022
Veronica Richardson, MSN	Nurse Planner	Membership on Advisory Committees or Review Panels, Board Membership, etc Boehringer-Ingelheim (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etcBristol-Myers Squibb - 05/01/2023
George Cotsarelis, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc Follica Consulting Fee-Eli Lilly Grant or research support-AbbVie, Inc. Grant or research support-JW Pharma Honoraria- Glaxo Smith Kline (Relationship has ended) - 11/22/2022
Misha A. Rosenbach, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. Consulting Fee-Merck & Co Consulting Fee-Processa Consulting Fee-Eli Lilly (Relationship has ended) Consulting Fee-Xentria (Relationship has ended) Grant or research support-Processa Consulting Fee-Janssen Pharmaceuticals (J&J) - 11/16/2022

Michelle Weir. MD	Other Planning Committee Member	Nothing to disclose - 11/17/2022
-------------------	------------------------------------	----------------------------------

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.